NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$21.99 USD
-0.18 (-0.81%)
Updated May 17, 2024 04:00 PM ET
After-Market: $22.01 +0.02 (0.09%) 5:10 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
NovoCure Limited [NVCR]
Reports for Purchase
Showing records 101 - 120 ( 210 total )
Company: NovoCure Limited
Industry: Medical Services
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
From Underneath The Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
4Q19 Financials; Interim LUNAR Data May Illuminate 2H20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Preliminary Q4:19: Slowing GBM Script Growth, but Increasing Rev per Patient
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
3Q19; Novocure Story Unchanged for Us, Awaiting LUNAR 2H20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Biotechnology - SITC 2019 Abstract Title Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
FDA Approval of TTFs for Mesothelioma Expands Cancer Tech Beyond Headwear
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
Biotechnology- ASCO Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
1Q19; Optune Doing Just Fine as Three Key Regulatory Catalysts Loom Over 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D